Wire · regulatory
HHS Names Acting Heads of CDER, CBER To Permanent Roles
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
The US Department of Health and Human Services named permanent directors for FDA centers CDER, CBER, and CTP, and appointed the first Deputy Commissioner for Technology and AI, signalling a focus on drug access, bio/pharma manufacturing, tobacco product regulation, and AI-driven technology modernization.
This Wire brief sits within Fusion42's coverage of Health, and 3 sources have reported it between 9 Sep 2026 and 10 Sep 2026.
◆ ◆ The Wire takeaway
You must now factor stable leadership at FDA’s drug and biologics centers into your US market strategy as regulatory review may accelerate with a fresh focus on safe, affordable medicines and bio-manufacturing. The creation of a Deputy Commissioner for AI means AI-driven product developers face a more coordinated regulatory approach starting now.
◆ Coverage
3 sources · first reported 9 Sep 2026 · latest 10 Sep 2026
◆ Related on Wire
◆ Topics